Browse the evidence

High sodium intake increases arterial stiffness independently of blood pressure by altering the extracellular matrix of arterial walls through MMP activation and TGF-β1 stimulation.

Reducing sodium not only lowers blood pressure but also directly improves the flexibility of your arteries, which is crucial for long-term heart health. This benefit occurs even if your blood pressure doesn't change significantly.

High fasting serum triglyceride levels (specifically 1.6–2.5 mmol/L) are a strong, independent risk factor for ischemic heart disease (IHD), even in individuals with high HDL cholesterol levels.

If you are a middle-aged or older man, your fasting triglyceride levels matter for your heart disease risk, even if your HDL (good cholesterol) is high. A level between 1.6 and 2.5 mmol/L is associated with a significantly higher risk of heart events. This suggests that managing triglycerides (often through diet, specifically reducing refined carbohydrates and alcohol) is crucial, regardless of your HDL status.

Experiencing weight discrimination is associated with a 60% increased risk of all-cause mortality, independent of BMI.

Recognize that social stress, including discrimination based on weight, has a measurable impact on longevity and health, independent of body weight. Reducing stigma and discrimination is a public health priority for improving mortality rates.

Obesity triggers insulin resistance and type 2 diabetes through chronic low-grade inflammation driven by visceral adipose tissue expansion, which releases pro-inflammatory cytokines (TNF-α, IL-6) and activates Toll-like receptors (TLR4) to interfere with insulin signaling.

Focus on reducing visceral fat through sustainable lifestyle changes, as this tissue actively drives inflammation and insulin resistance. Strategies should aim to lower systemic inflammation, potentially through dietary patterns that reduce saturated fats and improve gut health, as these are linked to the inflammatory response described.

Activation of the estrogen-related receptor alpha (Errα) by PGC-1α drives the expression of oxidative phosphorylation (OXPHOS) genes in skeletal muscle, and this pathway is downregulated in diabetic muscle.

This research identifies Errα as a critical 'switch' for mitochondrial energy production in muscle, which is often stuck 'off' in diabetes. While no direct supplement is named, the findings suggest that therapies activating Errα (agonists) could improve insulin sensitivity and energy metabolism in diabetic muscle without affecting liver glucose production.

Errα and Gabpa form a double-positive-feedback loop with PGC-1α to drive robust expression of mitochondrial genes, and this loop is disrupted in diabetic muscle.

Diabetic muscle has a broken feedback loop between PGC-1α, Errα, and Gabpa. Restoring this loop, potentially via Errα agonists, could improve mitochondrial function.

Obesity-induced infiltration of proinflammatory immune cells (macrophages and T cells) into skeletal muscle adipose depots (IMAT/PMAT) drives local inflammation, which impairs myocyte insulin signaling and contributes to systemic insulin resistance.

In obesity, fat storage around muscle fibers triggers an immune response that blocks insulin from working effectively in muscle cells. This is a biological inflammatory process, not just a dietary failure. Addressing the underlying inflammation through weight loss and metabolic health improvements can help restore insulin sensitivity.

Thiazolidinediones (PPAR-gamma agonists) improve insulin sensitivity and beta-cell function by enhancing adipocyte insulin sensitivity, inhibiting lipolysis, reducing plasma FFA, and redistributing fat away from visceral and hepatic depots to subcutaneous fat.

Thiazolidinediones (TZDs) are a class of diabetes medications that work by improving the function of fat cells. They help store fat in the right places (subcutaneous) rather than harmful places (liver, muscle), which reduces the toxic free fatty acids that cause insulin resistance. This improves how the body uses insulin and protects the pancreas.

Dysfunctional adipocytes in T2DM produce excessive insulin-resistant and inflammatory cytokines (e.g., resistin, TNF-alpha, IL-6, PAI-1) and secrete reduced amounts of insulin-sensitizing adipocytokines (e.g., adiponectin).

Fat tissue acts as an endocrine organ. In Type 2 Diabetes, fat cells become 'dysfunctional,' releasing too many inflammatory signals (like TNF-alpha and IL-6) that worsen insulin resistance, while releasing too few protective signals (like adiponectin) that help insulin work. This imbalance contributes to the progression of the disease.

Somatostatin infusion suppresses hyperglucagonemia and markedly reduces hyperglycemia in Type 1 Diabetic humans, even when insulin is reduced or discontinued.

In humans, suppressing glucagon with somatostatin lowers blood sugar even with low insulin. This supports the idea that targeting glucagon is a viable therapeutic strategy, though somatostatin's side effects limit its use.

Elevated plasma levels of specific ceramide subspecies (C18:0, C20:0, C24:1, C24:0) are associated with increased severity of insulin resistance in obese subjects with type 2 diabetes.

If you have type 2 diabetes, your body's fat metabolism produces specific lipids (ceramides) that interfere with how your cells respond to insulin. Higher levels of these lipids in your blood are linked to worse insulin resistance. While this paper doesn't prescribe a treatment, it highlights that managing lipid metabolism and inflammation is key to improving insulin sensitivity.

Plasma ceramide levels correlate with plasma TNF-α concentrations, suggesting a link between lipid accumulation and systemic inflammation in type 2 diabetes.

Inflammation and fat metabolism are connected in type 2 diabetes. High levels of certain fats (ceramides) in your blood are associated with higher levels of inflammatory markers (TNF-α). Reducing inflammation and managing fat metabolism may help address both issues.

High-fat diets induce metabolic endotoxemia by increasing intestinal permeability and LPS translocation, leading to chronic low-grade inflammation and insulin resistance via the TLR-4 pathway.

High-fat meals can cause a temporary spike in inflammatory markers (endotoxemia) by allowing bacterial toxins (LPS) to enter your bloodstream. This is more pronounced with high-fat diets than high-carb diets. Eating fiber and fruits with meals may help mitigate this inflammatory response.

Obesity-induced insulin resistance is mediated by an imbalance in pro- and anti-inflammatory adipokines, where increased pro-inflammatory adipokines (e.g., TNF-α, IL-6, leptin) and decreased anti-inflammatory adipokines (e.g., adiponectin) trigger inflammatory signaling cascades that suppress insulin receptor substrate (IRS) phosphorylation.

In obesity, fat tissue doesn't just store energy; it releases inflammatory signals (adipokines) that block insulin's action. This happens because the balance of these signals shifts towards inflammation (high TNF-alpha, IL-6, leptin) and away from protection (low adiponectin). Addressing insulin resistance requires understanding this inflammatory component, not just caloric intake.

Adipose tissue immune cell composition shifts in obesity from anti-inflammatory (M2 macrophages, Th2 T cells, Tregs) to pro-inflammatory (M1 macrophages, Th1 T cells, CD8+ T cells), driving local and systemic inflammation that contributes to insulin resistance.

Obesity changes the immune environment of fat tissue. Instead of anti-inflammatory cells that protect insulin sensitivity, pro-inflammatory immune cells (like M1 macrophages and Th1 T cells) take over, releasing chemicals that block insulin action.

Adiponectin, an anti-inflammatory adipokine, improves insulin sensitivity by activating AMPK to enhance fatty acid oxidation and glucose uptake, but its levels are decreased in obesity due to suppression by inflammatory signals.

Adiponectin helps muscles use glucose and fat for energy. In obesity, this protective hormone is suppressed by inflammation. Restoring adiponectin levels (e.g., through weight loss or exercise) can help restore insulin sensitivity.

Increased intramyocellular ceramide content in obese insulin-resistant humans is associated with impaired insulin-stimulated Akt phosphorylation and reduced glucose uptake.

In obese individuals with insulin resistance, high levels of a specific fat molecule called ceramide in muscle cells interfere with insulin's ability to signal for glucose uptake. This suggests that managing intramuscular lipid composition, particularly ceramides, is crucial for improving insulin sensitivity, potentially more so than just total fat mass.

Biologic mechanisms linking physical activity, sedentary behavior, and obesity to cancer risk include effects on endogenous insulin sensitivity, chronic sex steroids, metabolic hormones, and inflammation.

Understanding that exercise and weight management affect hormones and inflammation helps explain why these lifestyle factors prevent cancer.

Long-term transdermal testosterone gel (AndroGel) treatment in hypogonadal men maintains beneficial effects on sexual function, mood, lean body mass, fat mass, and bone mineral density without significant increases in muscle strength.

If you are a hypogonadal man, long-term use of testosterone gel (5-10g daily) effectively restores sexual function, improves mood, increases lean mass, and reduces fat mass. These benefits are maintained over several years. However, do not expect significant gains in muscle strength despite the increase in lean mass. Regular monitoring of prostate health and blood counts is essential to manage safety risks.

Obesity disrupts female fertility through multiple mechanisms including HPO axis deregulation, adipokine-mediated inflammation, and oocyte quality reduction, leading to anovulation and reduced IVF success rates.

If you are obese, your fertility is likely compromised even if your periods are regular. This is due to hormonal imbalances and inflammation affecting egg quality and implantation. Weight loss through lifestyle modification is proven to restore menstrual cyclicity and ovulation, improving conception chances.

Adipokines (leptin, adiponectin, resistin, etc.) released by adipose tissue in obesity directly interfere with ovarian function, insulin sensitivity, and endometrial receptivity, contributing to infertility.

Your fat tissue is not just storage; it acts as an endocrine organ releasing hormones that disrupt your reproductive system. This is why weight loss helps.

Peripheral endocannabinoid system overactivity in adipose and pancreatic tissues directly contributes to obesity-related metabolic dysregulation, including hyperinsulinemia, lipogenesis, and hypoadiponectinemia, independent of central appetite control.

This research suggests that obesity involves a dysregulated signaling system in fat and pancreatic cells that promotes fat storage and insulin resistance, regardless of how much you eat. While this paper does not prescribe a specific diet or exercise routine, it highlights that targeting these peripheral pathways (e.g., via medications like rimonabant, though withdrawn) addresses the root hormonal drivers of metabolic syndrome. For current practice, this underscores the importance of interventions that improve insulin sensitivity and reduce visceral fat, as these may help normalize endocannabinoid signaling.

Inhibition of the MAP kinase pathway (via MEK inhibition) enhances skeletal muscle myoblast differentiation, whereas activation of the PI 3-kinase/p70S6k pathway is essential for IGF-stimulated differentiation.

This research suggests that muscle cell differentiation is not simply the absence of growth signals. Instead, it requires a specific signal (PI 3-kinase pathway) to proceed, while the growth signal (MAPK pathway) actively suppresses it. For muscle building contexts, this implies that simply stopping cell division is not enough; specific molecular pathways must be activated to trigger the structural changes of differentiation.

In obese adults, excess visceral fat and insulin resistance are independently associated with incident prediabetes and type 2 diabetes, whereas general adiposity markers (BMI, total body fat, abdominal subcutaneous fat) are not.

If you are obese, your total weight or BMI is not the best predictor of your diabetes risk. Instead, focus on markers of 'dysfunctional adiposity': visceral fat (belly fat), insulin resistance, and liver fat. These specific factors drive the transition to prediabetes and diabetes, whereas general fat mass does not. Monitoring visceral fat and insulin sensitivity is more clinically relevant than tracking BMI alone.